表紙
市場調査レポート

PharmaPoint:過敏性腸症候群 (IBS) - 現在・将来の主要企業

PharmaPoint: Irritable Bowel Syndrome - Current and Future Players

発行 GlobalData 商品コード 325953
出版日 ページ情報 英文 54 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.51円で換算しております。
Back to Top
PharmaPoint:過敏性腸症候群 (IBS) - 現在・将来の主要企業 PharmaPoint: Irritable Bowel Syndrome - Current and Future Players
出版日: 2014年12月31日 ページ情報: 英文 54 Pages
概要

当レポートでは、世界の過敏性腸症候群 (IBS) の治療薬市場について調査分析し、市場を形成する主要企業 (新規参入企業を含む) に焦点を当てて、競合情勢について、体系的な情報を提供しています。

第1章 目次

第2章 イントロダクション

第3章 市場の見通し

  • 世界市場
    • 予測
    • 促進要因と障壁

第4章 現在・将来の主要企業

  • 概要
  • 企業戦略の動向
  • 企業プロファイル
    • Actavis
    • Astellas
    • Almirall
    • Ironwood
    • 武田薬品工業
    • Sucampo
    • Prometheus
    • Salix
    • Menarini
    • Synergy
    • AstraZeneca

第5章 付録

図表

目次
Product Code: GDHC1042FPR

GlobalData has released its pharma report, "PharmaPoint: Irritable Bowel Syndrome - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Irritable Bowel Syndrome Market. The report identifies and analyses the key companies shaping and driving the global Irritable Bowel Syndrome market. The report provides insight into the competitive Irritable Bowel Syndrome landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.

Scope

  • Investigation of current and future market competition for Irritable Bowel Syndrome
  • Competitor assessment
  • Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
  • Strategic assessment of Irritable Bowel Syndrome sector through market impact analysis, future market scenario and company analysis

Reasons to buy

  • Gain a high level view of the trends shaping and driving Irritable Bowel Syndrome market
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market
  • What's the next big thing in the global Irritable Bowel Syndrome market landscape? Identify, understand and capitalize

Table of Contents

1 . Table of Contents

  • 1.1 . List of Tables
  • 1.2 . List of Figures

2 . Introduction

  • 2.1 . Catalyst
  • 2.2 . Related Reports

3 . Market Outlook

  • 3.1 . Global Markets
    • 3.1.1 . Forecast
    • 3.1.2 . Drivers and Barriers - Global Issues

4 . Current and Future Players

  • 4.1 . Overview
  • 4.2 . Trends in Corporate Strategy
  • 4.3 . Company Profiles
    • 4.3.1 . Actavis
    • 4.3.2 . Astellas
    • 4.3.3 . Almirall
    • 4.3.4 . Ironwood
    • 4.3.5 . Takeda
    • 4.3.6 . Sucampo
    • 4.3.7 . Prometheus
    • 4.3.8 . Salix
    • 4.3.9 . Menarini
    • 4.3.10 . Synergy
    • 4.3.11 . AstraZeneca

5 . Appendix

  • 5.1 . Bibliography
  • 5.2 . Abbreviations
  • 5.3 . Methodology
  • 5.4 . Forecasting Methodology
    • 5.4.1 . Diagnosed IBS Patients
    • 5.4.2 . General Pricing Assumptions
    • 5.4.3 . Generic Erosion
  • 5.5 . Primary Research - KOLs Interviewed for This Report
  • 5.6 . About the Authors
    • 5.6.1 . Analyst
    • 5.6.2 . Therapy Area Director
    • 5.6.3 . Global Head of Healthcare
  • 5.7 . About GlobalData
  • 5.8 . Disclaimer

List of Tables

  • Table 1: Global Sales Forecasts ($m) for IBS, 2013-2023
  • Table 2: Global IBS Market - Drivers and Barriers, 2013-2023
  • Table 3: Key Companies in the IBS Market in the 7MM, 2014
  • Table 4: Actavis' IBS Portfolio Assessment, 2014
  • Table 5: Astellas' IBS Portfolio Assessment, 2014
  • Table 6: Almirall's IBS Portfolio Assessment, 2014
  • Table 7: Ironwood's IBS Portfolio Assessment, 2014
  • Table 8: Takeda's IBS Portfolio Assessment, 2014
  • Table 9: Sucampo's IBS Portfolio Assessment, 2014
  • Table 10: Prometheus' IBS Portfolio Assessment, 2014
  • Table 11: Salix's IBS Portfolio Assessment, 2014
  • Table 12: Menarini's IBS Portfolio Assessment, 2014
  • Table 13: Synergy's IBS Portfolio Assessment, 2014
  • Table 14: AstraZeneca's IBS Portfolio Assessment, 2014

List of Figures

  • Figure 1: Global Sales for IBS by Region, 2013-2023
  • Figure 2: Company Portfolio Gap Analysis in IBS, 2013-2023
  • Figure 3: Actavis' SWOT Analysis in IBS, 2013-2023
  • Figure 4: Astellas' SWOT Analysis in IBS, 2013-2023
  • Figure 5: Almirall's SWOT Analysis in IBS, 2013-2023
  • Figure 6: Ironwood's SWOT Analysis in IBS, 2013-2023
  • Figure 7: Takeda's SWOT Analysis in IBS, 2013-2023
  • Figure 8: Sucampo's SWOT Analysis in IBS, 2013-2023
  • Figure 9: Prometheus' SWOT Analysis in IBS, 2013-2023
  • Figure 10: Salix's SWOT Analysis in IBS, 2013-2023
  • Figure 11: Menarini's SWOT Analysis in IBS, 2013-2023
  • Figure 12: Synergy's SWOT Analysis in IBS, 2013-2023
  • Figure 13: AstraZeneca's SWOT Analysis in IBS, 2013-2023
Back to Top